A series of launches of targeted antibodies has enlarged the patient selection
As a series of anticancer drugs targeting a specific disease has acquired product approvals, it is expected that patients will have a larger choice.
Recently, Ono Pharmaceutical Korea has acquired a product approval for its PD-1 targeted antibody (indication for melanoma therapy) ‘Opdivo 20mg a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
